Anavex Life Sciences Corp (AVXL)

[RedShoulder]

I've been pounding the table over Missling not taking action on a super Ph-2 results with PDD/PD; all high dose patients improved; and OLE will likely show additional improvement. No drug has ever accomplished that. I may have to make an apology based on the speculation below, I hope so. ;>)

Interesting speculation from Veliger on the ST board:
---------------------------------------------------------------
"we haven’t seen a commitment to start a Phase 3 Parkinson’s study because they’re betting on not needing it. They are finalizing the 48-week PDD OLE…they’ll have the Alzheimer’s data in Q3…I fully expect that if the data is as good as I expect it to be for both the Alz and PDD OLE they will NOT need to run another trial for PDD, and this is the reason for the radio silence on Parkinson’s. They may need more time in clinic for PD motor-related impairments, but not dementia. I see no other explanation that makes logical sense."
----------------------------------------------------------------

Maybe that is the reason we are closing in on a year since the Ph-2 PDD/PD report came out showing improvement in all the patients on high dose; yet no indication of a start on Ph-3?

FDA has approved other drugs early on less convincing data than the 'all improved on high dose' of A2-73. No drug for PDD/PD has ever improved the condition until now with those treated with high dose A2-73. The speculation is a possible reason for the long overdue start of a Ph-3.